Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee

被引:108
作者
Eisinger, F
Alby, N
Bremond, A
Dauplat, J
Espie, M
Janiaud, P
Kuttenn, F
Lebrun, JP
Lefranc, JP
Pierret, J
Sobol, H
Stoppa-Lyonnet, D
Thouvenin, D
Tristant, H
Feingold, J
机构
[1] Inst J Paoli I Calmettes, INSERM, CRI 9703, Dept Prevent, F-13009 Marseille, France
[2] French Natl League Canc, Paris, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Jean Perrin Ctr, Clermont Ferrand, France
[5] St Louis Hosp, Paris, France
[6] Hop Henri Mondor, INSERM, SC 15, F-94010 Creteil, France
[7] Hop Necker Enfants Malad, Paris, France
[8] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
[9] INSERM, U304, Paris, France
[10] Inst Curie, Paris, France
[11] Univ Paris 08, Paris, France
[12] INSERM, U155, Paris, France
关键词
BRCA1; BRCA2; breast cancer; guidelines; ovarian cancer; preventive care;
D O I
10.1023/A:1008389021382
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Almost 10% of breast and ovarian cancers are familial, and the majority are linked to BRCA1 and BRCA2 germline mutations, Despite uncertainty about the management of female gene carriers, consensus guidelines have been established to assist practitioners and consultees in making health care decisions. Methodology: The Ad Hoc Committee was composed of 14 experts appointed by the French National Institute for Health and Medical Research, all of whom attended eleven workshops at which more than 3500 articles were systematically analyzed. Five additional experts critically analysed the first version of the report. Criteria and decision process: On a probability scale of the risk of developing breast or ovarian cancers, two thresholds were defined for use in determining whether an intervention would be worthwhile. The first is the threshold above which an intervention can be envisaged or recommended, and the second is the one below which an intervention can be ruled out: between the two, the decision has to be made on a case-by-case basis. Screening and preventive strategies analyzed. With respect to breast cancer: 1) hormonal interventions; 2) primary prevention (diet, family planning and chemoprevention); 3) screening (breast self-examination, clinician breast examination, tumor markers, imaging); 3) prophylactic mastectomy, With respect to ovarian cancer: 1! hormonal stimulation; 2) screening (clinical screening, ultrasound and tumor markers); 3) prophylactic oophorectomy. Main conclusions. For each strategy the following points were addressed: the information to be given to the consultee, the procedure and the indications. In addition, the committee's opinion about BRCA1 and BRCA2 mutation screening is that population-based, or even large-scale, implementation are not justified. Although no scientific evidence is available, the committee feels that specific management is indispensable and advocates the use of defined and evaluated procedures, and participation in clinical trials.
引用
收藏
页码:939 / 950
页数:12
相关论文
共 92 条
  • [1] ANDREWS L, 1995, AM J HUM GENET, V56, P327
  • [2] Experts argue about tamoxifen prevention trial
    Ault, A
    Bradbury, J
    [J]. LANCET, 1998, 351 (9109) : 1107 - 1107
  • [3] Breast self-examination and survival from breast cancer - A prospective follow-up study
    Auvinen, A
    Elovainio, L
    Hakama, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (02) : 161 - 168
  • [4] HIGH-FIBER DIETS AND REDUCED RISK OF BREAST-CANCER
    BAGHURST, PA
    ROHAN, TE
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (02) : 173 - 176
  • [5] BERMAN P, 1978, PUBLIC POLICY, V26, P157
  • [6] Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
    Berry, DA
    Parmigiani, G
    Sanchez, J
    Schildkraut, J
    Winer, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) : 227 - 238
  • [7] Biesecker B B, 1995, J Natl Cancer Inst Monogr, P115
  • [8] GENETIC-COUNSELING FOR FAMILIES WITH INHERITED SUSCEPTIBILITY TO BREAST AND OVARIAN-CANCER
    BIESECKER, BB
    BOEHNKE, M
    CALZONE, K
    MARKEL, DS
    GARBER, JE
    COLLINS, FS
    WEBER, BL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (15): : 1970 - 1974
  • [9] BROWN P, 1993, MONOGR NATL CANC I, P157
  • [10] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2
    Burke, W
    Daly, M
    Garber, J
    Botkin, J
    Kahn, MJE
    Lynch, P
    McTierman, A
    Offit, K
    Perlman, J
    Petersen, G
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12): : 997 - 1003